News & Events
BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned with FDA Moderniziation Act 2.0
Stockholm, Sweden and Edinburgh, UK, 28 May 2026 BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned […]
Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment
Sundbyberg, April 16, 2026 Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB co […]
Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
Sundbyberg, September 29, 2025 Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics BioLami […]
-
Featured May 28, 2026
BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned with FDA Moderniziation Act 2.0
Stockholm, Sweden and Edinburgh, UK, 28 May 2026 BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned […]
-
Featured April 17, 2026
Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment
Sundbyberg, April 16, 2026 Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB co […]
-
Publications February 2, 2026
Biolaminin 521 supports animal origin-free hESC-RPE differentiation and retinal rescue
This study demonstrates that combining a fully defined, animal origin-free culture medium with a physiologically relevant extracellular matrix is ke […]
-
Publications December 10, 2025
Biolaminin®-functionalized Biosilk scaffolds model dopaminergic neurogenesis in ventral midbrain organoids
By using a Biolaminin 111–functionalized Biosilk scaffold, the system produces organoids with stable cell-type composition, reliable dopaminergic […]
-
Publications December 8, 2025
Biosilk/Biolaminin® system supports long-term, uniform 3D neural tissue development
Biosilk and Biolaminin 521 enabled centimeter-scale, channel-permeated 3D cultures that differentiated uniformly into neuroectoderm followed by furt […]
-
Publications December 5, 2025
Biosilk recreates native tissue properties in 3D culture
Biosilk brings 3D culture closer to native tissue biology by providing an ECM-like microfiber architecture that supports firm cell attachment, sprea […]
-
Publications November 13, 2025
Laminin-augmented extracellular matrix improves human brain reconstruction
Brain organoids are valuable for modeling human brain development and disease but often lack the complex extracellular matrix (ECM) cues needed for […]
-
Featured September 30, 2025
Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
Sundbyberg, September 29, 2025 Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics BioLami […]
-
Featured September 4, 2025
Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies
Sundbyberg, September 4, 2025 Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies Pluristy […]
-
Featured March 3, 2025
BioLamina appoints Brian Hawkins, PhD as new Chief Technology Officer (CTO).
Stockholm, March 3, 2025 BioLamina appoints Brian Hawkins, PhD, as new Chief Technology Officer (CTO). BioLamina AB, appoints Brian Hawkins as Chief […]
-
Featured December 6, 2024
Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx
Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx We are proud to have been chosen by PluriStyx as their […]
-
Featured November 19, 2024
Webinar: Treating Blindness with Stem Cell Therapies
How close are we to one-shot stem cell therapies for eye disease? What are the critical factors for successful translation to the […]
-
Past events August 21, 2024
Join us for our webinar with Prof. Dr. Kasri – neurodevelopmental disorder research with MEA and laminin
Join us for our webinar “Neurons are talking…are you listening?” with Prof. Dr. Kasri from Radboud UMC — Bridging the gap between […]
-
Featured August 15, 2024
BioLamina AB appoints Klaus Langhoff-Roos as new CEO.
Stockholm August 15, 2024 BioLamina appoints Klaus Langhoff-Roos as new CEO. BioLamina AB, a leading maker of reagents for stem and primary […]
-
Past events June 13, 2024
Meet us at ISSCR 2024, July 10–13
Meet us at ISSCR 2024, July 10–13 We look forward to meeting you at ISSCR 2024, July 10–13 in Hamburg, Germany. Meet […]
-
Past events April 23, 2024
Meet us at ISCT 2024, May 29–June 1
Meet us at ISCT 2024, May 29–June 1 We are looking forward to meeting you at ISCT 2024, May 29–June 1 in […]